CN109321651A - A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism - Google Patents
A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism Download PDFInfo
- Publication number
- CN109321651A CN109321651A CN201811270460.0A CN201811270460A CN109321651A CN 109321651 A CN109321651 A CN 109321651A CN 201811270460 A CN201811270460 A CN 201811270460A CN 109321651 A CN109321651 A CN 109321651A
- Authority
- CN
- China
- Prior art keywords
- seq
- probe
- fam
- cyp2d6 gene
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the compositions for detecting people's CYP2D6 gene pleiomorphism, the composition includes the primer for detecting CYP2D6 gene C 188T and/or G4268C loci polymorphism, and the primer for detecting C188T includes sequence primer as shown in SEQ ID NO.1, SEQ ID NO.2 and/or SEQ ID NO.3；The primer in the detection site G4268C includes sequence primer as shown in SEQ ID NO.4, SEQ ID NO.5 and/or SEQ ID NO.6.The primer that the present invention detects C188T is combined with the primer of detection G4268C, can detect the polymorphism of C188T, G4268C simultaneously, specificity is high, and sensitivity is good, reproducible.
Description
Technical field
The invention belongs to the nucleic acid detection technique fields in a kind of field of biomedicine clinical detection technique, and in particular to arrive
A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism.
Background technique
Polymerase chain reaction (PCR) technology is one of most common technique in current detection of nucleic acids, wherein using fluorescence mark
The real-time fluorescent PCR technology of the taqman sonde method of note detection of nucleic acids, clinical diagnosis and in terms of
Using highly developed, which is had been applied in numerous industries such as laboratory research, food safety, medical and health, but
It is that these technologies mostly use greatly single reaction tube to detect single target nucleotide, when in the multiple target nucleotides of single reaction tube detection
When, the primer and probe sequence of different target nucleotides is detected due to introduce simultaneously, these introduce primer and probes can because
There is hybridization from each other and generate interference, simultaneously as 188 sites of mankind's CYP2D6 gene, 4268 sites all only have one
Point mutation, extremely difficult find can distinguish wild type and saltant type, and the primer that can will not be interfered with each other in single tube again is visited
Needle design.Meanwhile it as soon as needing to evade false negative as a kit and needing to be added internal reference target nucleic acid sequence and can detect
The primed probe of internal reference target nucleic acid sequence exacerbates the difficulty of Single-tube multiplex-PCR technology.
Currently, the method for Genotyping mainly has the restricted Length Polymorphism technique of PCR sequencing PCR, polymerase chain reaction-, core
Piece method and fluorescence quantitative PCR method etc..It is higher to obtain that these technologies all have to pass through cumbersome nucleic acid extraction, purification process
The template DNA of purity.The step of increasing operation, it is time-consuming and laborious, and increase false positive rate caused by manual operation error and vacation yin
Property rate.
CN201610771855.3 discloses the Pyrosequencing primer pair and reagent of qualitative detection CYP2D6 Genotyping
Box.The primer pair includes positive amplimer, reversed amplimer, sequencing primer, and positive amplimer and reversed amplification are drawn
5 ' ends of object carry out biotin labeling respectively；The invention further relates to a kind of pyrosequencings of qualitative detection CYP2D6 Genotyping
Kit.The kit includes amplimer, PCR reaction solution 1, PCR reaction solution 2, sequencing primer, Uracil DNA Glycosylase
Enzyme and Taq polymerase.The present invention has that testing result is accurate, specificity is high, detection cycle is short, easy to operate and can effectively meet
The advantages of clinical examination requires；It can real-time monitoring reaction process, reaction time be short, PCR product simple process is in addition, also having
Pyrophosphoric acid sequencer and high-throughput sample detection can be gone up, and than goldstandard method, i.e. Capillary Electrophoresis PCR sequencing method sensitivity
Higher advantage.
CN200610072593.8 discloses a set of for detecting the oligonucleotides of CYP450 enzyme gene hot mutant site
Probe and application thereof, probe separately design on each hypotype enzyme dna complete genome sequence of CYP450, sensitivity with higher and spy
It is anisotropic.
Summary of the invention
In view of the deficiencies of the prior art, the technical problem to be solved in the present invention is more to provide a kind of detection people CYP2D6 gene
Composition, kit, sample treatment and the application of state property, primer are not interfere with each other, and specificity is high, and sensitivity is good, are repeated
Property is good.
In a first aspect, the present invention provides a kind of composition for detecting people CYP2D6 gene pleiomorphism,
The composition includes the primer for detecting CYP2D6 gene C 188T and/or G4268C loci polymorphism,
The primer of detection 188 loci polymorphism of CYP2D6 gene includes sequence such as SEQ ID NO.1, SEQ ID
Primer shown in NO.2 and SEQ ID NO.3；The primer of the detection G4268C loci polymorphism includes sequence such as SEQ ID
Primer shown in NO.4, SEQ ID NO.5 and SEQ ID NO.6.
The composition further includes the probe for detecting CYP2D6 gene 188 and/or 4268 loci polymorphisms, the inspection
The probe for surveying 188 loci polymorphism of CYP2D6 gene includes sequence probe as shown in SEQ ID NO.9, the detection CYP2D6
The probe in 4268 site of gene includes sequence probe as shown in SEQ ID NO.10；Or the SEQ ID NO.9, SEQ ID
Probe shown in NO.10 is modified by the fluorescent marker of different Detection wavelengths, and the fluorescent marker is CY5 or FAM.
The composition further include interior label primer for detecting CYP2D6 gene 188 and/or 4268 loci polymorphisms and
Internal standard probe, the interior label primer sequence is as shown in SEQ ID NO.7 and/or SEQ ID NO.8, and the internal standard probe sequence is such as
Shown in SEQ ID NO.11.
The present invention also provides a kind of kit, the kit contains PCR detection reagent A and PCR detection reagent B,
The PCR reaction solution A includes sequence such as SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.4, SEQ ID
A variety of primers of NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11
And probe, detect 188 site of CYP2D6 gene, 4268 site wild types.
The PCR reaction solution B includes sequence respectively such as SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5, SEQ
ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, a variety of of SEQ ID NO.11 draw
Object and probe detect 188 site of CYP2D6 gene, 4268 site mutation types.
The kit further includes sample lysate, and the sample lysate includes Tris-HCl buffer, dodecyl
Sodium sulphate, EDTA, glycerol and Proteinase K.Usually also containing protein denaturants and surface-actives such as glycerol, PEG8000, polysorbas20s
Agent.
The kit further include: 1 wild type control product, 1 saltant comparison product and 1 blank control product；It is described
Wild type control product are to include the recombinant plasmid of CYP2D6 gene polymorphism sites 188C, 4268G and include internal standard base
The mixture of the recombinant plasmid of cause；The saltant comparison product be include CYP2D6 gene polymorphism sites 188T, 4268C
Recombinant plasmid and include internal standard gene recombinant plasmid mixture；The blank control product are polymorphic not comprising CYP2D6
The physiological saline in property site and internal standard gene.The carrier of the recombinant plasmid is preferably pUC57.
The present invention also provides a kind of sample treatment, this method uses kit, includes the following steps:
1) 2 parts of human genome sample of nucleic acid pre-processed are taken, 2 parts of samples (are detected with the PCR reaction solution A respectively
Reagent A 39.4ul+ enzymatic mixture 0.6ul) and PCR reaction solution B (detection reagent B 39.4ul+ enzymatic mixture 0.6ul) mixing,
Wherein, probe shown in SEQ ID NO.9 is by FAM fluorescent marker, and probe shown in SEQ ID NO.10 is by CY5 fluorescent marker, SEQ
Probe shown in ID NO.11 is by HEX/VIC fluorescent marker；
Pcr amplification reaction is carried out, CY5, FAM, HEX/VIC fluorescence signal are acquired；
2) result judges: is automatically saved after reaction as a result, according to the Start of image adjustment Baseline after analysis
(user can voluntarily adjust according to the actual situation, and Start value can in 3~15, End value for value, End value and Threshold value
Be located at 5~20, adjust negative control amplification curve it is straight or lower than threshold line)；When wild type control product and saltant comparison
Product have CY5, FAM, HEX/VIC fluorescence signal initial line and CT≤35, blank control product without CY5, FAM, HEX/VIC initial line,
When sample detection pipe HEX/VIC initial line and CT≤35, judgment experiment success；Believed according to CY5 fluorescence in 2 sample detection pipes A, B
Number 4268 site of Δ Ct value situation interpretation CYP2D6 gene parting；According to FAM fluorescence signal in 2 sample detection pipes A, B
188 site of Δ Ct value situation interpretation CYP2D6 gene parting；If there is FAM and/or CY5 without the case where CT value display,
This data CT value is denoted as 40 to be included in the calculating of Δ Ct.
The pretreatment of the human genome sample of nucleic acid includes:
Buccal swab liquid: taking 50ul human mouth swab liquid to be placed in 1.5mlEP pipe, and 50ul sample lysate, piping and druming is added
It mixes, is stored at room temperature 10min；
Anticoagulated whole blood: taking 50ul anticoagulated whole blood to be placed in 1.5mlEP pipe, 100 μ L erythrocyte cracked liquids, pipettor is added
Piping and druming mixes for several times, and 10000rpm/min is centrifuged 1min and abandons supernatant, adds 50 μ L sample lysates, is stored at room temperature 10min, shakes
Swing mixing.
The program of pcr amplification reaction includes:
Genotyping interpretation follows following rule:
Calculation: Δ CtFAM=CtFAM(B)-CtFAM(A)-(CtHEX(B)-CtHEX(A))
ΔCtCY5=CtCY5(B)-CtCY5(A)-(CtHEX(B)-CtHEX(A))
When the probe shown in the SEQ ID NO.11 is by VIC fluorescent marker, CtHEXFor CtVIC；
The present invention also provides a kind of application of kit in terms of detecting people CYP2D6 gene pleiomorphism.
Foregoing probes have meaning well-known to those skilled in the art, for can be with the single-stranded combination of target nucleic acid that amplifies
Single stranded DNA.In general, 5 ' end mark fluorescent groups of the nucleotide sequence in every kind of probe, 3 ' end label quenching groups.Using
Fluorophor and quenching group can be commercially available, can such as use FAM/SYBR-GREEN, VIC/JOE/HEX, NED/
The conventional products such as TAMRA/CY3, ROX/Texas Red and CY5, their Detection wavelength is different, can also be with authorized company
Directly synthesize the probe for having fluorescent marker.Probe shown in SEQ ID NO.9,10,11 of the present invention can be respectively by different detection waves
Long fluorescent marker modification, the fluorescent marker are CY5, VIC or FAM；As a specific example, the fluorescence mark that each target nucleic acid uses
Note is as follows:
Each target nucleic acid corresponds to fluorescent species
| Type | Probe | Fluorescence | Wavelength nm |
| 188 site of CYP2D6 gene | SEQ ID NO.9 | FAM | 520±5 |
| 4268 site of CYP2D6 gene | SEQ ID NO.10 | CY5 | 650±5 |
| Internal reference | SEQ ID NO.11 | VIC | 550±5 |
The PCR reaction solution A detects 188 site of CYP2D6 gene, 4268 site wild types, PCR reaction solution B detection
188 site of CYP2D6 gene, 4268 site mutation types.
Optionally, the PCR reaction solution A or B also contain taq DNA polymerase, magnesium chloride, dNTPs (dATP,
DCTP, dGTP and dTTP), internal reference nucleic acid.
Fluorescence signal arrival fluorescent PCR instrument, which is defaulted, in Fluorescence PCR, in each PCR reaction tube of Ct value expression sets
Recurring number experienced, with good reproducibility, therefore is used as the good finger of judging result when fixed threshold value
Mark.The threshold value of default setting is preferably 10 times of the standard deviation of the fluorescence signal of 3-10 circulation.
Optionally, the human genome sample of nucleic acid may be from blood, blood product, cast-off cells.The PCR amplification is anti-
System is answered to use pH buffer, such as N, N- bicine N--KOH buffer.The pcr amplification reaction system uses
Salt, such as KCl.The pcr amplification reaction system has used albumen enzymatic protective reagent, such as BSA (bovine serum albumin(BSA)).The PCR expands
Increase reaction system and used glycerol, activity of enzyme under the conditions of PCR can be extended.
Real time fluorescent PCR method sample detected is the vitro samples containing target nucleic acid, such as blood, blood product, is taken off
Fall cell etc..The real time fluorescent PCR method is only limitted to the detection to vitro samples, and the direct result of detection is the base of target nucleic acid
Because of parting.Sample is the mixed liquor that of short duration standing is mixed by sample lysate and sample of the invention, unavailable other methods
The nucleic acid solution of enrichment is detected, and has the risk of failure or false negative.
In the present invention, it is in a same vessel that " single PCR reaction tube ", which refers to the real time fluorescent PCR method technically,
It carries out, it is not necessary that replacement container.Wherein the container is PCR reaction tube for optimal selection, other can carry out PCR reaction simultaneously
The container that can carry out real-time fluorescence detection is also within the scope of the present invention.In real-time PCR method of the invention, same
The step of PCR amplification and real-time detection can be completed in a container, whole process need not replace container, thus facilitate operation
Person.Operator only needs that sample and various reagents are added into container, so that it may pass through commercially available common real-time fluorescence PCR
Instrument is automatically performed the detection of genetic loci of interest, very convenient in user, is also convenient for mechanical realizing automation.
Herein, " Multiple detection " refers to while detecting a variety of target nucleic acids, i.e., at least one.In first party of the invention
In the method in face, due at least having detected internal reference and a kind of nucleic acid, the nucleic acid of detection at least there are two types of.When detecting
Target nucleic acid type more than one when, while detect nucleic acid increase accordingly.Wherein, every kind of nucleic acid can only be DNA.In the present invention
Specific embodiment in, preferential selection carries out two re-detections, three re-detections detection.
Specific primed probe design of the invention are as follows:
For 188 site of CYP2D6 gene, according to the literature, preferably its highly conserved region is as amplification region, needle
Primer pair sequence to region design is wild primers SEQ ID NO.1 and mutant primers SEQ ID NO.2, and downstream is drawn
Object is that sequence is SEQ ID NO.3, and probe sequence is SEQ ID NO.9.
For 4268 site of CYP2D6 gene, according to the literature, preferably its highly conserved region is as amplification region, needle
Primer pair sequence to region design is wild primers SEQ ID NO.4 and mutant primers SEQ ID NO.5, and downstream is drawn
Object is that sequence is SEQ ID NO.6, and probe sequence is SEQ ID NO.10.
After 188 site of CYP2D6 gene, 4268 site primer probe sequences and reaction density has been determined, design is added
Internal reference primed probe as kit control false negative.The internal reference target that this kit uses is human genome
A kind of house-keeping gene, corresponding primer are SEQ ID NO.7 and SEQ ID NO.8, and fluorescence probe is SEQ ID NO.11.
As an example, PCR reaction system A are as follows:
PCR reaction system B can are as follows:
| Serial number | Component | Final concentration |
| 1 | N, N- bicine N--KOH buffer ph8.2 | 100mM |
| 2 | Potassium acetate | 125mM |
| 3 | Glycerol glycerol | 8% (V.V) |
| 4 | BSA | 20μg/ml |
| 5 | KCl | 5mM |
| 6 | Edta | 1μM |
| 7 | Tth DNA polymerase | 1U/test |
| 8 | Taq DNA polymerase | 2U/test |
| 9 | dntps | 2mM |
| 10 | MgCl2 | 2.5mM |
| 11 | SEQ ID NO.2 | 15pmol/test |
| 12 | SEQ ID NO.3 | 15pmol/test |
| 13 | SEQ ID NO.5 | 15pmol/test |
| 14 | SEQ ID NO.6 | 15pmol/test |
| 15 | SEQ ID NO.7 | 15pmol/test |
| 16 | SEQ ID NO.8 | 15pmol/test |
| 17 | SEQ ID NO.9 | 5pmol/test |
| 18 | SEQ ID NO.10 | 5pmol/test |
| 19 | SEQ ID NO.11 | 5pmol/test |
Optionally, the pcr amplification reaction includes:
Optionally,
Fourth aspect, the answering in detection people CYP2D6 gene pleiomorphism the present invention provides aforementioned composition or kit
With.Each sequence involved by this paper is specifically shown in sequence table or following table:
| SEQIDNO.1 | GAAGAGGAGCATTGAGGACC |
| SEQIDNO.2 | GAAGAGGAGCATTGAGGACT |
| SEQIDNO.3 | ACTATCTTCTCTACTGACATT |
| SEQIDNO.4 | GTGCACGAGGTCCAGAGATACA |
| SEQIDNO.5 | GTGCACGAGGTCCAGAGATACC |
| SEQIDNO.6 | TAAGTTTGTTTCTCCTACA |
| SEQIDNO.7 | TGAAAAACAACCATTGGCCG |
| SEQIDNO.8 | TGAAAAACAACCATTGGCCA |
| SEQIDNO.9 | CTGGCCAACATGGTGAAA |
| SEQIDNO.10 | GCCAGGAGATCATCGACC |
| SEQIDNO.11 | GCCAGGAGATCATCGACT |
The beneficial effects of the present invention are:
The present inventor passes through to be studied repeatedly, develops the hands-free fluorescence quantifying PCR method reagent for taking, directly expanding, and
Design screened mankind's CYP2D6 gene 188 sites, 4268 site wild types and mutant primers and probe each pair, optimization
Sample treatment, the use concentration of primer, probe, enzyme, dNTPs and other chemical reagent, is opened finally in optimizing reaction system
Issue the system that multiple target nucleic acids are detected in single reaction tube, and overcome multiple real time fluorescence PCR exploitation in encounter it is more
Weight primer/probe cross contamination and the relatively low technological difficulties of detection sensitivity, and detected relative to single tube, it saves big
Measure manpower, material resources and financial resources and time.By the verifying repeatedly of a large amount of samples, presently commercially available conventional fluorescent PCR is can be used in the present invention
Equipment is not necessarily to any transformation, can achieve the purpose that carry out parting, specificity, sensitivity, repeatability etc. to CYP2D6 gene
Technical indicator is reached advanced world standards.
Specifically, the present invention has the effect that
It 1, can be with quick release human blood sample or buccal swab suspension using the sample lysate of kit of the present invention
Genomic nucleic acids in sample, entire process of testing, only need to be directly molten with sample by sample without the DNA individually extracted in sample
Solution liquid is sufficiently mixed the template that can be used as PCR amplification, reduces operating procedure, avoids the ring in conventional nucleic acid extraction process
Border pollution.
2, using kit of the present invention can quickly to people's CYP2D6 gene carry out parting, have it is simple and quick, it is quick
The advantages such as sensitivity is high, high specificity, and as a result interpretation is objective.
3, probe used in this kit is Taqman probe, low in cost；Meanwhile all reaction whole process stopped pipes of the invention
It carries out, does not have to recycle product, purify after PCR reaction, digestion, electrophoresis, both saved testing cost, shorten
Detection cycle also reduces the pollution of false positive caused by PCR product.
4, this kit includes the primer and probe of internal standard gene, by the detection to internal standard gene, is reduced because of operation
The false negative that process generates.
5, kit of the present invention is using common fluorescent quantitative PCR platform, and platform use scope is wide, relative to sequencing
Method, chip method are easier to realize high-throughput detection, are more able to satisfy clinical needs.
Detailed description of the invention
Fig. 1-6 is the testing result figure of the gene pleiomorphism of embodiment 1.
Wherein Fig. 1-3 is PCR reaction system A respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC；Figure
4-6 is PCR reaction system B respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC.
Fig. 7-12 is the testing result figure of the gene pleiomorphism of embodiment 2.
Wherein Fig. 7-9 is PCR reaction system A respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC；Figure
10-12 is PCR reaction system B respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC.
Figure 13-18 is the testing result figure of the gene pleiomorphism of embodiment 3.
Wherein Figure 13-15 is PCR reaction system A respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC；
Figure 16-18 is PCR reaction system B respectively in the fluorescent quantitation amplification curve diagram of channel FAM, CY5 and VIC.
Specific embodiment
Hereafter probe used, the synthesis of primer commission hundred Li Ge biotech company of Shanghai, chemical reagent buying used is westerly
Lattice Ma aldrich (Shanghai) trade Co., Ltd, DNA polymerase used come from precious bioengineering (Dalian) limited public affairs
Department.
Hereafter used kit composition is as follows:
The composition of 1 kit of table
PCR reaction system A are as follows:
PCR reaction system B are as follows:
| Serial number | Component | Final concentration |
| 1 | Bicine-Koh ph8.2 | 100mM |
| 2 | K-acetate | 125mM |
| 3 | glycerol | 8% (V.V) |
| 4 | BSA | 20μg/ml |
| 5 | KCl | 5mM |
| 6 | Edta | 1μM |
| 7 | Tth DNA polymerase | 1U/test |
| 8 | Taq DNA polymerase | 2U/test |
| 9 | dntps | 2mM |
| 10 | MgCl2 | 2.5mM |
| 11 | SEQ ID NO.2 | 15pmol/test |
| 12 | SEQ ID NO.3 | 15pmol/test |
| 13 | SEQ ID NO.5 | 15pmol/test |
| 14 | SEQ ID NO.6 | 15pmol/test |
| 15 | SEQ ID NO.7 | 15pmol/test |
| 16 | SEQ ID NO.8 | 15pmol/test |
| 17 | SEQ ID NO.9 | 5pmol/test |
| 18 | SEQ ID NO.10 | 5pmol/test |
| 19 | SEQ ID NO.11 | 5pmol/test |
The operating procedure of kit is used in implementation
(1) sample preprocessing
Buccal swab: taking 50 μ L human mouth swab suspensions with 1.5mL EP pipe, and 50ul sample lysate is added, and piping and druming is mixed
It is even, it is stored at room temperature 10min；
Anticoagulated whole blood: it takes 50ul anticoagulated whole blood to be placed in 1.5mlEP pipe and 100 μ L erythrocyte cracked liquids is added, pipettor is blown
It beats and mixes for several times, 10000rpm/min is centrifuged 1min and abandons supernatant, adds 50 μ L sample lysates, is stored at room temperature 10min, shakes
It mixes；
(2) by two portions of 10ul sample mixed liquors respectively with 40ul reaction system CYP2D6 gene PCR reaction solution A, CYP2D6
Gene PCR reaction solution B mixing, then eight union of PCR is placed in fluorescent PCR instrument and carries out fluorescent PCR amplified reaction, acquisition CY5,
FAM, VIC fluorescence signal；
(3) result judges: is automatically saved after reaction as a result, according to the Start of image adjustment Baseline after analysis
(user can voluntarily adjust according to the actual situation, and Start value can in 3~15, End value for value, End value and Threshold value
Be located at 5~20, adjust negative control amplification curve it is straight or lower than threshold line)；When positive control Guan Jun has CY5, FAM, VIC
Fluorescence signal initial line and CT≤35, negative control without CY5, FAM initial line but have VIC fluorescence signal initial line and CT≤35, sample
When detection pipe VIC initial line and CT≤35, judgment experiment success；According to the Δ Ct of CY5 fluorescence signal in 2 sample detection pipes A, B
It is worth the parting in 4268 site of situation interpretation CYP2D6 gene；According to the Δ Ct value of FAM fluorescence signal in 2 sample detection pipes A, B
The parting in 188 site of situation interpretation CYP2D6 gene；Under the premise of internal standard is successful, if it is aobvious without CT value FAM and/or CY5 occur
When the case where showing, this data CT value is denoted as 40 and is included in the calculating of Δ Ct.(4) PCR amplification condition setting is as follows:
Genotype interpretation method:
Calculation: Δ CtFAM=CtFAM(B)-CtFAM(A)-(CtHEX(B)-CtHEX(A))
ΔCtCY5=CtCY5(B)-CtCY5(A)-(CtHEX(B)-CtHEX(A))
When the probe shown in the SEQ ID NO.11 is by VIC fluorescent marker, CtHEXFor CtVIC；
1 three re-detection of embodiment (188 heterozygotes, 4268 homozygotes).
The sample is detected using the above method, as a result as shown in Figure 1, genotype is 188CT, 4268CC.
In Fig. 1, in the left hand view in the channel FAM, abscissa 1-40 is divided into 1, and ordinate is -0.33446-
1.59350 being divided into 0.21422.The right part of flg in the channel FAM and the coordinate values of left hand view are identical.
The coordinate values in the channel CY5 are identical identical with the coordinate values in the channel FAM.
In the left hand view in the channel VIC, abscissa 1-40 is divided into 1, and ordinate is -0.68039-1.56561, interval
It is 0.249555.The right part of flg in the channel VIC and the coordinate values of left hand view are identical.
2 three re-detection of embodiment (188 homozygotes, 4268 heterozygotes)
The sample is detected using the above method, as a result as shown in Fig. 2, the sample genotype is 188CC,
4268GC。
In Fig. 2, the coordinate values in the channel FAM are identical with the coordinate values in the channel FAM in Fig. 1.
The coordinate values in the channel CY5 are identical identical with the coordinate values in the channel FAM.
The coordinate values in the channel VIC are identical with the coordinate values in the channel VIC in Fig. 1.
3 three re-detection of embodiment (188 homozygotes, 4268 homozygotes)
The sample is detected using the above method, as a result as shown in figure 3, the sample genotype is 188TT,
4268GG。
In Fig. 3, the coordinate values in the channel FAM are identical with the coordinate values in the channel FAM in Fig. 1.
The coordinate values in the channel CY5 are identical identical with the coordinate values in the channel FAM.
The coordinate values in the channel VIC are identical with the coordinate values in the channel VIC in Fig. 1.
<110>Hunan Jian Ji Bioisystech Co., Ltd
<120>a kind of composition, kit, sample treatment and application for detecting people CYP2D6 gene pleiomorphism
<160>11
<210>1
<211>20
<212>DNA
<213>artificial sequence
<400>1
gaagaggagcattgaggacc 20
<210>2
<211>20
<212>DNA
<213>artificial sequence
<400>2
gaagaggagcattgaggact 20
<210>3
<211>21
<212>DNA
<213>artificial sequence
<400>3
actatcttctctactgacatt 21
<210>4
<211>22
<212>DNA
<213>artificial sequence
<400>4
gtgcacgaggtccagagataca 22
<210>5
<211>22
<212>DNA
<213>artificial sequence
<400>5
gtgcacgaggtccagagatacc 22
<210>6
<211>19
<212>DNA
<213>artificial sequence
<400>6
taagtttgtttctcctaca 19
<210>7
<211>20
<212>DNA
<213>artificial sequence
<400>7
tgaaaaacaaccattggccg 20
<210>8
<211>20
<212>DNA
<213>artificial sequence
<400>8
tgaaaaacaaccattggcca 20
<210>9
<211>18
<212>DNA
<213>artificial sequence
<400>9
ctggccaacatggtgaaa 18
<210>10
<211>18
<212>DNA
<213>artificial sequence
<400>10
gccaggagatcatcgacc 18
<210>11
<211>18
<212>DNA
<213>artificial sequence
<400>11
gccaggagatcatcgact 18
Claims (10)
1. a kind of for detecting the composition of people's CYP2D6 gene pleiomorphism, characterized in that the composition includes for detecting
The primer of CYP2D6 gene 188 and/or 4268 loci polymorphisms,
It is described detection 188 loci polymorphism of CYP2D6 gene primer include sequence such as SEQ ID NO.1, SEQ ID NO.2 and
Primer shown in SEQ ID NO.3；The primer of the detection G4268C loci polymorphism includes sequence such as SEQ ID NO.4, SEQ
Primer shown in ID NO.5 and SEQ ID NO.6.
2. composition as described in claim 1, characterized in that the composition further includes for detecting CYP2D6 gene 188
And/or 4268 loci polymorphism probe, it is described detection 188 loci polymorphism of CYP2D6 gene probe include sequence such as SEQ
The probe of probe shown in ID NO.9, detection 4268 site of CYP2D6 gene includes sequence as shown in SEQ ID NO.10
Probe；Or probe shown in the SEQ ID NO.9, SEQ ID NO.10 is repaired by the fluorescent marker of different Detection wavelengths
Decorations, the fluorescent marker are CY5 or FAM.
3. composition as described in claim 1, characterized in that the composition further includes for detecting CYP2D6 gene 188
And/or 4268 loci polymorphism interior label primer and internal standard probe, the interior label primer sequence such as SEQ ID NO.7 and/or SEQ
Shown in ID NO.8, the internal standard probe sequence is as shown in SEQ ID NO.11.
4. a kind of includes the kit of the composition as described in claim any one of 1-3, characterized in that the kit contains
PCR detection reagent A and PCR detection reagent B,
The PCR detection reagent A includes sequence such as SEQ ID NO.1, SEQ ID NO.3, SEQ ID NO.4, SEQ ID
A variety of primers of NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11
And probe；
The PCR detection reagent B includes sequence respectively such as SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.5, SEQ ID
A variety of primers of NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11
And probe.
5. kit as claimed in claim 4, characterized in that the kit further includes sample lysate, and the sample is molten
Solving liquid includes Tris-HCl buffer, lauryl sodium sulfate, EDTA, glycerol and Proteinase K.
6. kit as described in claim 4 or 5, characterized in that further include: 1 wild type control product, 1 saltant type pair
According to product and 1 blank control product；The wild type control product be include CYP2D6 gene polymorphism sites 188C, 4268G
Recombinant plasmid and include internal standard gene recombinant plasmid mixture；The saltant comparison product be include CYP2D6 base
Because polymorphic site 188T, 4268C recombinant plasmid and include internal standard gene recombinant plasmid mixture；The blank
Reference substance is the physiological saline not comprising CYP3D6 gene polymorphism sites.
7. a kind of sample treatment, characterized in that this method uses the described in any item kits of claim 4-6, including
Following steps:
1) 2 parts of human genome sample of nucleic acid pre-processed are taken, 2 parts of samples are reacted with the PCR reaction solution A and PCR respectively
Liquid B mixing, wherein probe shown in SEQ ID NO.9 is by FAM fluorescent marker, and probe shown in SEQ ID NO.10 is by CY5 fluorescence mark
Note, probe shown in SEQ ID NO.11 is by HEX/VIC fluorescent marker；
Pcr amplification reaction is carried out, CY5, FAM, HEX/VIC fluorescence signal are acquired；
2) result judges: when wild type control product and saltant comparison product have CY5, FAM, VIC fluorescence signal initial line and CT≤
35, blank control is without CY5, FAM, HEX/VIC initial line, sample detection pipe HEX/VIC initial line and CT≤35, judgment experiment success；
According to the parting in 4268 site of Δ Ct value situation interpretation CYP2D6 gene of CY5 fluorescence signal in 2 sample detection pipes A, B；Root
According to the parting in 188 site of Δ Ct value situation interpretation CYP2D6 gene of FAM fluorescence signal in 2 sample detection pipes A, B；If occurring
When the case where FAM and/or CY5 is shown without CT value, this data CT value is denoted as 40 and is included in the calculating of Δ Ct.
8. the method for claim 7, characterized in that the program of pcr amplification reaction includes:
9. method as claimed in claim 7 or 8, characterized in that Genotyping interpretation follows following rule:
Calculation: Δ CtFAM=CtFAM(B)-CtFAM(A)-(CtHEX(B)-CtHEX(A))
ΔCtCY5=CtCY5(B)-CtCY5(A)-(CtHEX(B)-CtHEX(A))
When the probe shown in the SEQ ID NO.11 is by VIC fluorescent marker, CtHEXFor CtVIC,
10. a kind of application such as the kit of claim 4,5 or 6 in terms of detecting people CYP2D6 gene pleiomorphism.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811270460.0A CN109321651A (en) | 2018-10-29 | 2018-10-29 | A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811270460.0A CN109321651A (en) | 2018-10-29 | 2018-10-29 | A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109321651A true CN109321651A (en) | 2019-02-12 |
Family
ID=65259179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811270460.0A Pending CN109321651A (en) | 2018-10-29 | 2018-10-29 | A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109321651A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110184343A (en) * | 2019-06-26 | 2019-08-30 | 湖南健基生物技术有限公司 | Detect composition, kit, method and the application of CYP2C9 and VKORC1 gene pleiomorphism |
| CN112501265A (en) * | 2020-09-24 | 2021-03-16 | 杭州百迈生物股份有限公司 | Reagent, detection method and kit for detecting CYP2D6 gene |
| CN114277190A (en) * | 2021-12-31 | 2022-04-05 | 安徽中盛溯源生物科技有限公司 | Specific DNA fragment, primer, kit and detection method for detecting foreign gene residues in hiPSC |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103088156A (en) * | 2012-12-26 | 2013-05-08 | 杭州三合创新科技有限公司 | White spot syndrome virus detection kit and method |
| CN104894236A (en) * | 2015-04-30 | 2015-09-09 | 武汉友芝友医疗科技有限公司 | Human CYP2D6 and SULT1A1 gene polymorphism detection kit |
| CN105861703A (en) * | 2016-05-16 | 2016-08-17 | 钟诗龙 | Kit for simultaneously detecting multisite mutation of genes CYP2C19 and CYP2D6 |
| CN106755360A (en) * | 2016-12-06 | 2017-05-31 | 武汉海吉力生物科技有限公司 | Nucleic acid, kit and method for detecting mankind's CYP2D6 gene pleiomorphisms |
| CN107227361A (en) * | 2017-06-29 | 2017-10-03 | 庄江兴 | Primer, probe and detection kit for detecting CYP2C19 gene pleiomorphisms |
-
2018
- 2018-10-29 CN CN201811270460.0A patent/CN109321651A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103088156A (en) * | 2012-12-26 | 2013-05-08 | 杭州三合创新科技有限公司 | White spot syndrome virus detection kit and method |
| CN104894236A (en) * | 2015-04-30 | 2015-09-09 | 武汉友芝友医疗科技有限公司 | Human CYP2D6 and SULT1A1 gene polymorphism detection kit |
| CN105861703A (en) * | 2016-05-16 | 2016-08-17 | 钟诗龙 | Kit for simultaneously detecting multisite mutation of genes CYP2C19 and CYP2D6 |
| CN106755360A (en) * | 2016-12-06 | 2017-05-31 | 武汉海吉力生物科技有限公司 | Nucleic acid, kit and method for detecting mankind's CYP2D6 gene pleiomorphisms |
| CN107227361A (en) * | 2017-06-29 | 2017-10-03 | 庄江兴 | Primer, probe and detection kit for detecting CYP2C19 gene pleiomorphisms |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110184343A (en) * | 2019-06-26 | 2019-08-30 | 湖南健基生物技术有限公司 | Detect composition, kit, method and the application of CYP2C9 and VKORC1 gene pleiomorphism |
| CN112501265A (en) * | 2020-09-24 | 2021-03-16 | 杭州百迈生物股份有限公司 | Reagent, detection method and kit for detecting CYP2D6 gene |
| CN114277190A (en) * | 2021-12-31 | 2022-04-05 | 安徽中盛溯源生物科技有限公司 | Specific DNA fragment, primer, kit and detection method for detecting foreign gene residues in hiPSC |
| CN114277190B (en) * | 2021-12-31 | 2024-07-23 | 安徽中盛溯源生物科技有限公司 | Specific DNA fragment, primer, kit and detection method for detecting exogenous gene residues in hiPSC |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113502335B (en) | Molecular marker related to sheep growth traits and application thereof | |
| CN111235272A (en) | Composition for one-time detection of lung cancer multiple gene mutation and application thereof | |
| AU2015213570B2 (en) | NGS systems control and methods involving the same | |
| CN109321651A (en) | A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism | |
| CN106939334B (en) | Method for detecting fetal DNA content in plasma of pregnant woman | |
| CN109182493B (en) | Primer and kit for detecting human 16p11.2 microdeletion syndrome and detection method thereof | |
| CN102286616A (en) | Method and kit for detecting mycobacterium tuberculosis isoniazide drug resistant gene mutation | |
| CN109295192A (en) | A kind of composition, kit, sample treatment and application detecting people MDR1 gene pleiomorphism | |
| CN109371113A (en) | A kind of composition, kit, sample treatment and application detecting mankind's APOE and SLCO1B1 gene pleiomorphism | |
| CN108060213A (en) | Isothermal duplication method detection SNP site probe and kit based on the recombinase-mediated that probe is oriented to | |
| CN110607381A (en) | Mycobacterium tuberculosis detection kit and method | |
| CN114085926B (en) | Primer, probe, kit and detection method for SNP locus polymorphism of ABCB1 gene C3435T | |
| CN111593115B (en) | Primer and probe combination and kit for multiplex real-time fluorescence PCR detection of beta-thalassemia gene mutation | |
| CN110004215A (en) | Mankind's mthfr gene polymorphic detection kit | |
| CN107177688A (en) | The kit of the deaf susceptibility gene mutation of detection and its application | |
| CN107043808A (en) | UGT1A1 genetic polymorphism detection primer peptide nucleic acids and its kit | |
| CN110241231A (en) | Detect composition, kit, method and the application of CYP2C19 gene pleiomorphism | |
| CN105969842A (en) | Glu504lys detection genotyping kit based on AllGlo probe and genotyping method thereof | |
| CN111793676A (en) | Method and kit for detecting gene polymorphism and application thereof | |
| CN112029851A (en) | Method and kit for detecting gene polymorphism of clopidogrel medication and application of kit | |
| CN116024349B (en) | Primer probe combination and kit for methylation detection of cervical cancer | |
| CN103451300B (en) | Deaf sick tumor susceptibility gene GJB2 235delC, 299delAT mutation detection kit | |
| CN114703306B (en) | Detection method and kit for mycoplasma genitalium parC gene mutation type | |
| CN113564240B (en) | HLA-B27 allele detection method and detection kit | |
| CN103451301B (en) | Deaf sick tumor susceptibility gene SLC26A4 2168A > G, IVS7-2A > G mutation detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |